Axatilimab: First Approval

Susan J. Keam

doi:10.1007/s40265-024-02109-1

2024-11-18

PRE

Susan J. Keam *

DOI：10.1007/s40265-024-02109-1

原文链接

原文求助

摘要

En 中文

Axatilimab (NIKTIMVO (TM); axatilimab-csfr), an anti-colony-stimulating Factor 1 Receptor (CSF-1R) humanized IgG4 (kappa light chain) monoclonal antibody, is being developed by Incyte Corporation and Syndax Pharmaceuticals for the treatment of chronic graft-versus-host disease (cGVHD) and other indications, including idiopathic pulmonary fibrosis (IPF). In August 2024, axatilimab was approved in the USA for the treatment of cGVHD after failure of at least two prior lines of systemic therapy in adult and paediatric patients weighing at least 40 kg. Axatilimab was added to the NCCN guidelines for cGVHD in August 2024. This article summarizes the development milestones leading to this first approval of axatilimab for the treatment of cGVHD.

Keyword:

CSF1R

期刊

Drugs

IF:

14.4

论文数:

8.4K

被引数:

2.3W

机构

暂无机构信息

引用论文

Axatilimab in Recurrent or Refractory Chronic Graft-versus-Host Disease

NEW ENGLAND JOURNAL OF MEDICINE

IF78.5

2024-09-19

PREAI

Wolff, Daniel; Cutler, Corey; Lee, Stephanie J.; Pusic, Iskra; Bittencourt, Henrique; White, Jennifer; Hamadani, Mehdi; Arai, Sally; Salhotra, Amandeep; Perez-Simon, Jose A.; Alousi, Amin; Choe, Hannah; Kwon, Mi; Bermudez, Arancha; Kim, Inho; Socie, Gerard; Chhabra, Saurabh; Radojcic, Vedran; O'Toole, Timothy; Tian, Chuan; Ordentlich, Peter; Defilipp, Zachariah; Kitko, Carrie L.

Localization of Ligand-Binding Domains of Human Corticotropin-Releasing Factor Receptor: A Chimeric Receptor Approach

Molecular Endocrinology

IF0

1997-06-01

OAAI

Chen W. Liaw; Dimitri E. Grigoriadis; Timothy W. Lovenberg; Errol B. De Souza; Richard A. Maki

CSF1R Blockade for Refractory Chronic Graft-versus-Host Disease

NEW ENGLAND JOURNAL OF MEDICINE

IF78.5

2024-09-19

PREAI

Mohty, Mohamad

The training and expectations of medical students in Mozambique

Human Resources for Health

IF0

2007-04-19

OAAI

Fernando Sousa; João Schwalbach; Yussuf Adam; Luzia Gonçalves; Paulo Ferrinho

Impact of the COVID-19 Pandemic on the Reported Incidence of Select Bacterial Enteric Diseases in Canada, 2020

Foodborne Pathogens and Disease

IF0

2023-03-01

OAAI

Brendan Dougherty; Russell O. Forrest; Courtney R. Smith; Vanessa Morton; Lauren M. Sherk; Brent Avery; Ashley Kearney; Sara Christianson; Celine Nadon; M. Kate Thomas

CSF-1R inhibitor PLX3397 attenuates peripheral and brain chronic GVHD and improves functional outcomes in mice

JOURNAL OF NEUROINFLAMMATION

IF10.1

2023-12-15

OAAI

Shaikh, Samreen N.; Willis, Emily F.; Dierich, Max; Xu, Yi; Stuart, Samuel J. S.; Gobe, Glenda C.; Bashaw, Abate A.; Rawashdeh, Oliver; Kim, Seung Jae; Vukovic, Jana

CSF-1-dependant donor-derived macrophages mediate chronic graft-versus-host disease

JOURNAL OF CLINICAL INVESTIGATION

IF13.6

2014-08-26

169

OAAI

Alexander, Kylie A.; Flynn, Ryan; Lineburg, Katie E.; Kuns, Rachel D.; Teal, Bianca E.; Olver, Stuart D.; Lor, Mary; Raffelt, Neil C.; Koyama, Motoko; Leveque, Lucie; Le Texier, Laetitia; Melino, Michelle; Markey, Kate A.; Varelias, Antiopi; Engwerda, Christian; Serody, Jonathan S.; Janela, Baptiste; Ginhoux, Florent; Clouston, Andrew D.; Blazar, Bruce R.; Hill, Geoffrey R.; MacDonald, Kelli P. A.

Targeting CSF-1R represents an effective strategy in modulating inflammatory diseases

PHARMACOLOGICAL RESEARCH

IF10.5

2023-01-01

OAAI

Xiang, Caigui; Li, Heng; Tang, Wei

Targeting CSF1R in Chronic GVHD - Lessons in Translation

NEW ENGLAND JOURNAL OF MEDICINE

IF78.5

2024-09-19

PREAI

Sarantopoulos, Stefanie

没有更多内容